Use of Anticholinergic and Antifungal Pharmacotherapy for the Management of Bronchorrhea in a Patient With BRAF-mutated Adenocarcinoma of the Lung
In the palliative care of patients with non-small cell lung cancer (NSCLC), bronchial hypersecretion (bronchorrhea) may cause additional dyspnea and impaired quality of life. Bronchorrhea is defined as mostly aqueous sputum production with a volume of> 100ml / 24 hours. Various treatment options have been described in case reports and small series, including the use of tyrosine kinase inhibitors such as gefitinib and erlotinib, somatostatin analogues (octreotide), macrolide antibiotics, anti-inflammatory drugs (indomethacin, corticosteroids) and anticholinergics.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Fabian Leo, Lisa Alexander, Hannes Semper, Christian Groh é Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Corticosteroid Therapy | Indomethacin | Lung Cancer | Non-Small Cell Lung Cancer | Pain | Pain Management | Palliative | Palliative Care | Tarceva